Celldex Therapeutics (CLDX) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Celldex (CLDX) Bullish Stance Reiterated at Cantor Fitzgerald Following Q1 and Update
April 30, 2015 9:42 AM EDTCantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and $38 price target on Celldex Therapeutics (NASDAQ: CLDX) following in-line Q1 results and an pipeline update.
The analyst notes that at the end of the quarter, Celldex had $360 million in cash. "This seems sufficient to us to last into 2017, though could be impacted by the regulatory and commercialization plans for Rintega (rindopepimut),"... More
